Disease Diagnosis TRIZ Cases

Nasal fluid testing of UGT8 and BUD31 enables objective, non-invasive early diagnosis of cognitive dysfunction in companion animals.

Amniotic fluid biomarkers such as RARRES2 and LGALS3BP help distinguish symptomatic from asymptomatic fetal CMV infection prenatally.

Skin TSLP screening identifies infants at risk of atopic allergy early, enabling preventive use of TSLP inhibitors or moisturizers.

A handheld lateral flow assay quantifies thrombomodulin in blood to rapidly detect internal hemorrhage outside hospital settings.

Specific immunohistochemistry staining detects CLEVER-1 positive tumor cells for machine-readable anti-CLEVER-1 patient selection.

Urinary Ephrin-B1 measurement enables earlier nephrotic syndrome diagnosis and progression monitoring before proteinuria fully develops.

Specific SMYD3 autoantibody detection in blood enables earlier, non-invasive lupus diagnosis with high sensitivity and specificity.

Colloidal gold antibody capture and an Aβ-binding test line enable sensitive urine screening for early MCI and Alzheimer's risk.

Combining KDIGO stage with HSPA1B, IL8, and GZMB data enables early SA-AKI risk stratification and timely renal protective therapy.

Nematode chemotaxis toward pet urine enables low-cost cancer screening with strong sensitivity and specificity in dogs, cats, and rodents.

IL-10-producing ILC2s suppress allogeneic T cell responses to limit GVHD while maintaining graft function and the graft-versus-leukemia effect.

Paired biopsy CD8+ T-cell density changes enable earlier prediction of immunotherapy benefit, reducing ineffective treatment exposure.

Two-step nanotube-catalyzed hydrothermal carbonization boosts electrode conductivity and repeatability for vardenafil detection in serum and urine.

Combining VASP phosphorylation and platelet tissue factor detection improves identification of residual thrombotic risk during antiplatelet treatment.

Combined protein, lipid, and metabolite biomarkers separate MASLD into three molecular subtypes, improving diagnosis and treatment selection.

Immunohistochemistry staining of tumor biopsies measures CLEVER-1 positive cells to identify patients likely to respond to anti-CLEVER-1 therapy.

Recombinant bacteriophages plus cefoxitin enable rapid, sensitive MRSA nasal swab detection while reducing false positives and PCR cost.

Glycan biomarker levels in saliva and urine enable more accessible TBI detection than subjective exams or costly imaging, including mild cases.

An eight-group, 5-tube flow cytometry panel standardizes clonal disease screening to improve accuracy, automation, and rare lesion detection.

Integrated microfluidic channels and imaging identify invasive tumor cell subpopulations for survival prediction, recurrence risk, and therapy screening.

Epitope-specific NT-proBNP antibodies improve specificity and sensitivity for earlier canine heart disease diagnosis and prognosis.

Quantifying BCL-2, BCL-xL, and MCL-1 in leukemic stem cells improves prediction of response to Venetoclax and related therapies.

Combined liver, serum, and urine biomarkers classify heterogeneous MASLD into molecular subtypes to improve diagnosis and guide subtype-matched treatment.

Multi-marker DCIS tissue analysis predicts ipsilateral recurrence risk, helping tailor therapy and avoid unnecessary radiation or hormone treatment.

Direct bonding of biomolecule probes to epoxy resins removes surface functionalization steps, improving assay consistency and reducing processing time.

Multiple host biomarkers are scored together to rapidly distinguish bacterial, viral, and mixed infections and reduce unnecessary antibiotic use.

Image-based reaction well alignment enables single-sample macroarray testing with automatic biomarker recognition and ready-to-use reagents.

Ion mobility lipoprotein subfraction measurement replaces labor-intensive direct testing to improve insulin resistance risk prediction in clinical use.

Combining troponin with BMP10, FGF23, BNP-type peptide, cMyBPC, or ANG2 improves early discrimination between type 1 and type 2 MI.

sBCMA blood testing tracks tumor burden and therapy response faster than M-protein and more reliably than sFLC in renal impairment.

Precombined phospholipids, activators, tissue factor, and plasmin speed blood testing for sensitive detection of hyperfibrinolysis and shutdown.

ELISPOT detection of CNS antigen-reactive B cells in PBMCs helps diagnose multiple sclerosis and predict relapse risk and therapy response.

A phospholipid, activator, tissue factor, and plasmin composition speeds whole-blood detection of hyperfibrinolysis and fibrinolytic shutdown.